Clinical trials: Endocrine Disorders, open to volunteers
- Condition Endocrine Disorders
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Type 2 Diabetes
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of HRS-4729 Injection in participants with type 2 diabetes who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of…
- Trial name
- NCT07843862
- Testing
- HRS-4729 Injection, Mazdutide
- Where
- 2 sites in China
- Volunteers
- 240 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers
The purpose of this clinical investigation is to evaluate the safety and efficacy of Amnion/Chorion/Amnion allograft , Amnion/Chorion allograft, and/or Amnion/Amnion allograft, plus Standard of Care (SOC) each versus SOC alone in…
- Trial name
- NCT06681428
- Testing
- Allograft
- Where
- 9 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tides Medical
Obesity, Overweight
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without…
- Trial name
- Elecoglipron (NCT07775404)
- Testing
- Elecoglipron
- Where
- 49 sites in China, Hong Kong and 3 more
- Volunteers
- 351 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males
This study is a single-center, randomized, double-blind, placebo- and active-controlled, parallel-group, single-ascending dose (SAD) design.
- Trial name
- NCT07630233
- Testing
- UBT38006, Insulin Degludec Injection, Insulin Icodec Injection
- Where
- China
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Type 2 Diabetes
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）
This multicenter, randomized, double-Blind, parallel-group, placebo-controlled phase III trial is to evaluate the efficacy and safety of UBT251 Injection in patients with Type 2 Diabetes Mellitus with inadequate glycemic control…
- Trial name
- UNIGUIDE-1 (NCT07659574)
- Testing
- UBT251 Injection 2.0 mg, UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg
- Where
- China
- Volunteers
- 360 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Ovarian Cancer
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated…
- Trial name
- NCT07069335
- Testing
- Olaparib 150 MG
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetic Kidney Disease, Chronic Kidney Disease
Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product
The purpose of this study is to evaluate the long-term safety, efficacy, and durability in participants with chronic kidney disease (CKD) who received up to four REACT injections, delivered percutaneously into either the same or…
- Trial name
- NCT06790498
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Prokidney
Diabetic Retinopathy, DR
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic…
- Trial name
- NCT05296447
- Testing
- Standard of Care, Aflibercept
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- AbbVie
Adult Growth Hormone Deficiency
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
This is a multiple-dose, dose-escalation, randomized, double-blind, placebo-controlled phase Ⅱa clinical trial. A total of 36 adult participants with growth hormone deficiency will be enrolled sequentially in ascending dose…
- Trial name
- NCT07551804
- Testing
- Inpegsomatropin Injection
- Where
- 6 sites in China
- Volunteers
- 36 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Cholecystitis, Cholecystitis, Chronic
Shortwave Infrared Surgical Imaging Device Study
The goal of this observational study is to perform an in-human assessment of an investigational shortwave infrared (SWIR) imaging device, aimed to enhance the visualization of critical anatomical structures during surgical…
- Conditions
- Cholecystitis, Cholecystitis, Chronic, Chronic Calculous Cholecystitis, Primary Hyperparathyroidism
- Trial name
- NCT07744425
- Testing
- Observational study of SWIR imaging device in surgery
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cision Vision, Inc.
Obesity, Type 2 Diabetes Mellitus
Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay
This is a Phase 4 observational study evaluating the safety and effectiveness of tirzepatide (T.G.) manufactured by INDUFAR S.A.
- Conditions
- Obesity, Type 2 Diabetes Mellitus, Overweight With Comorbidities
- Trial name
- NCT07492563
- Testing
- Tirzepatide (T.G.)
- Where
- Paraguay
- Volunteers
- 300 people
- Sponsor
- LABORATORIOS INDUFAR
Ovarian Cancer, Breast Cancer
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced…
- Conditions
- Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer
- Trial name
- LNCB74-01 (NCT06774963)
- Testing
- LNCB74
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- LigaChem Biosciences, Inc.
Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
- Conditions
- Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07223047
- Testing
- BMS-986523, Gemcitabine, Nab-Paclitaxel
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 252 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer, Esophageal Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
- Trial name
- NCT05983432
- Testing
- BL-B01D1
- Where
- 37 sites in United States, France and 3 more
- Volunteers
- 540 people
- Sponsor
- SystImmune Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in…
- Trial name
- INAVO123 (NCT06790693)
- Testing
- Inavolisib, CDK4/6i, Letrozole
- Where
- 242 sites in United States, Argentina and 18 more
- Volunteers
- 450 people
- Sponsor
- Hoffmann-La Roche
Relapsed/Refractory Ovarian Carcinoma
Study of NTB-928 in R/R OC
The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the…
- Trial name
- NCT07690189
- Testing
- NTB-928
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- TeneoSeven, Inc.
Type 1 Diabetes, Type 2 Diabetes
Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes
This study will collect sensor data in subjects with T1D or T2D, 2-80 years of age.
- Trial name
- NCT07864168
- Testing
- Next Generation Extended Wear Sensors
- Where
- 18 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Medtronic MiniMed, Inc.
Pancreatic Cancer
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced …
- Trial name
- ARTIA-Pancreas (NCT05764720)
- Testing
- Daily Adaptive External Beam Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 134 people
- Sponsor
- Varian, a Siemens Healthineers Company
Type 2 Diabetes, Insulin Dependent Diabetes
Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes
This observational study aims to collect detailed metabolic and physiologic data from adults with insulin-dependent type 2 diabetes mellitus following consumption of a mixed meal tolerance test.
- Trial name
- MT2D (NCT07650682)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology